Treatment and follow-up of low-risk patients with thyroid cancer

Nature Reviews Endocrinology

Volumn 7, Issue 10, 2011, Pages 625-628

  Schlumberger, Martin ^a   Borget, Isabelle ^a   Nascimento, Camila ^a   Brassard, Maryse ^a   Leboulleux, Sophie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

CANCER THERAPY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

HUMANS; IODINE RADIOISOTOPES; RISK FACTORS; THYROGLOBULIN; THYROID NEOPLASMS; THYROXINE;

EID: 80053216905     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.133     Document Type: Review

References (28)

1. Cooper, D. S. et al. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
2. Pacini, F. et al. European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur. J. Endocrinol. 154, 787-803 (2006). (Pubitemid 43997716)
3. Smallridge, R. C. et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH stimulated thyroglobulin in follow-up of thyroid cancer patients. J. Clin. Endocrinol. Metab. 92, 82-87 (2007). (Pubitemid 46075007)
4. Schlumberger, M. et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J. Clin. Endocrinol. Metab. 92, 2487-2496 (2007).
5. Iervasi, A. et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 67, 434-441 (2007). (Pubitemid 47283844)
6. Rosario, P. W. & Purisch, S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 (Pubitemid 351257849)
7. Spencer, C., Fatemi, S., Singer, P., Nicoloff, J. & Lopresti, J. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 20, 587-595 (2010).
8. Rosario, P. W., Xavier, A. C. & Calsolari, M. R. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21, 49-53 (2011).
9. Tala Jury, H. P. et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J. Clin. Endocrinol. Metab. 95, 230-237 (2010).
10. Vaisman, A. et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32, 689-698 (2010).
11. Nascimento, C. L. et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr. Relat. Cancer 18, 29-40 (2011).
12. Grunwald, F, Menzel, C, Fimmers, R., Zamora, P. O. & Biersack, H. J. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J. Nucl. Med. 37, 1962-1964 (1996). (Pubitemid 26428362)
13. Toubeau, M. et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J. Nucl. Med. 45, 988-994 (2004). (Pubitemid 47611686)
14. Kim, T. Y. et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 1440-1445 (2005).
15. Hay, I. D. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26, 879-885 (2002). (Pubitemid 36920280)
16. Jonklaas, J. et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20, 1423-1424 (2010).
17. Durante, C. et al. Papillary Thyroid Cancer Study Group. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J. Clin. Endocrinol. Metab. 95, 4882-4888 (2010).
18. Brassard, M. et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J. Clin. Endocrinol. Metab. 96, 1352-1359 (2011).
19. Malandrino, P. et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of Basal serum thyroglobulin. J. Clin. Endocrinol. Metab. 96, 1703-1709 (2011).
20. Drummond, M. F., Sculpher, M., Torrance, G. W., O'Brien, B. J. & Stoddart, G. L. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn (Oxford University Press, USA, 2005).
21. Bonnet, S. et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J. Clin. Endocrinol. Metab. 94, 1162-1167 (2009).
22. Hwang, H. S. & Orloff, L. A. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope 121, 487-491 (2011).
23. Leboulleux, S. et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92, 3590-3594 (2007). (Pubitemid 47435339)
24. Tuttle, R. M. & Leboeuf, R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol. Metab. Clin. North Am. 37, 419-435 (2008). (Pubitemid 351698090)
25. Baudin, E. et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up following thyroid hormone withdrawal, in thyroid cancer patients. J. Clin. Endocrinol. Metab. 88, 1107-1111 (2003). (Pubitemid 36337763)
26. Chiovato, L. et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 139, 346-351 (2003).
27. Catargi, B. et al. Comparison of four strategies of radioiodine ablation in patients with thyroid cancer with low-risk of recurrence: the randomized, prospective ESTIMABL study on 753 patients. Presented at the 35th International Thyroid Congress, Paris, September 2010
28. Mallick, U. et al. HILO: multicentre randomised phase III clinical trial of high vs low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer. Presented at the 35th International Thyroid Congress, Paris, September 2010